I n this issue of the Journal, Lipkus and others 1 present a study describing the influence of patient numeracy on the understanding of treatment benefits communicated using the prediction model Adjuvant Online (or Adjuvant! for short). Increasingly, oncologists and their patients have access to such models, enabling them to calculate individualized probabilities of outcomes such as survival or chance of recurrence. Adjuvant! is probably the most widely used, but other models are finding their way into the consulting room too, such as Oncotype DX 2 (Genomic Health, Redwood City, CA) for breast and colon cancer and the Kattan nomograms for prostate cancer. 3 The models generally provide pretreatment prognostic information to estimate the benefit that patients may obtain from various available treatment options.
Adjuvant! is a Web-based program that calculates individualized, 10-year disease-free survival probabilities and predicts the benefit of adjuvant systemic therapy (see www.adjuvantonline.com). 4 The models have generally been developed to support decision making of oncologists but are increasingly being used in clinical encounters with patients. However, patient communication regarding the probabilities from these models is not straightforward. Little research on the impact of using these models with patients has been made available, but we know from the vast literature on risk communication that patients have difficulty understanding risks. The article by Lipkus and others 1 confirms this.
Adjuvant! has been implemented widely, a practice that may be seen as remarkable in view of the complexities inherent to risk communication. It is therefore important that studies that assess patients' understanding of the output from the model and its impact on decision making, such as that of Lipkus and others, 1 are carried out in clinical practice. Their study is not only of interest because of the findings related to patient numeracy but also, and perhaps even more so, because of the overall picture it paints of patients' understanding, or lack of understanding, of the model's output.
The results are disconcerting, as the authors rightly conclude, and confirm that 30% to 40% of women were unable to correctly identify the treatment that maximized cancer-free survival. Furthermore, less than half of the patients provided a correct estimate of their 10-year disease-free survival after surgery, and this figure dropped to less than 1 in 5 for estimates provided after the various adjuvant therapies. This study is not the first to show the difficulty that patients have with understanding the Adjuvant! printouts. [5] [6] [7] It seems that the information is simply too complex, even for patients high in numeracy, although they admittedly do fare better.
In the discussion section of their article, Lipkus and others 1 suggest replacing the Adjuvant! bar charts, shown in Figure 1 , with simpler graphics proposed by Zikmund-Fisher and others, 7 who found that the use of pictographs instead of bars (and the addition of the word more in the legend: ''x more women of 100 are alive because of therapy'') doubled the proportion of women responding correctly. However, a much larger improvement (resulting in 2 out of 3 women answering correctly) was obtained by using a 2-option graph instead of the 4option one and by omitting the ''no additional therapy'' and ''chemotherapy only'' options. This was legitimate, as argued by the authors, ''because the physician in our scenario strongly recommended hormonal therapy.'' 7(p3385) This suggestion therefore implies that to help patients reach a decision, providers have to limit patients' decisional control by preselecting the treatment options to present. However, because we know that clinicians and patients often disagree about whether treatments are worthwhile, this approach could undermine shared decision making, essentially throwing the baby out with the bath water.
Correlations between the printout estimates and the patients' answers ranged from 0.37 to 0.48 only, despite all patients having received the Adjuvant! printouts for reference while answering the questions, and despite time provided to patients to discuss the printout with their oncologist. It seems that patients either did not understand the printout or did not feel it necessary to refer to it while answering the questions. Unfortunately, the study does not provide an answer to which (if either) was the case, but perhaps the striking absence of a difference between patients with low and high numeracy at low levels of survival gives us a hint ( Figure 2 ). Could it be that oncologists, when considering patients at the lower end of the survival spectrum, felt the decision to be so strongly in favor of additional therapy that they preferred not to dwell on the Adjuvant! results and simply recommended treatment? The range of estimates of 10-year diseasefree survival was wide: 10% to 90% with no further treatment and a 15% minimum estimate shown for maximal-combined therapy. How many oncologists would focus a patient's attention on such a disheartening figure or give such devastating information to the patient to take home (had it not been for the study)? Furthermore, how many patients would not rather deny these figures 8 and therefore disregard the printout?
An earlier study by Tzeng and others 2 on patient understanding of Oncoprint DX provides an indication that such a process may have occurred. That study found a recalled recurrence risk that correlated much more strongly with patients' actual recurrence risk (r = 0.7). Indeed, in that study, the lowest 10-year disease-free survival (after hormonal therapy) was 68%, a far less bleak figure than that of 14% in the study by Lipkus and others. 1 The population of that study, from the early days of Oncoprint DX, was a selected sample. Most subjects were Caucasian, had at least a college degree, reported high household income, and had health insurance. Furthermore, the Oncoprint DX Web site provided support to oncologists in communicating information to patients and support to patients in understanding the results. It is likely that all these factors contributed to more extensive doctorpatient discussions of the options and risks, leading to better understanding and recall of the information.
The medical decision-making community, known to combine an interest in both modeling and doctorpatient decision making, faces a big challenge. We are able to build increasingly sophisticated models, not only in oncology but in many other clinical fields. This is undoubtedly valuable when these models serve to provide the clinician with more individualized figures, but we still have a long way to go before these models can be wholeheartedly recommended as patient decision support tools for clinical use. To adequately communicate risk predictions in the clinical encounter, we need more than just the numbers. Even graphical support does not guarantee success. We need to develop simpler graphics while avoiding oversimplification and develop methods to better train clinicians to effectively communicate the meaning of these graphically enhanced results. To achieve this, we first need to learn more about the way in which information is currently communicated to patients in the clinical encounter. Unfortunately, none of these studies 1,2,5,6 has worked to assess and understand this communication process. We need studies that will do so, not only for Adjuvant! and Oncoprint DX but also for other prediction models increasingly being used to inform patients and assist them in making difficult decisions.
